When Two Outta Three Is Bad…For Patients, Regulators And Biopharma

By Troy Short, Chief Operating Officer

Developing advanced therapies often presents biotech companies with difficult tradeoffs between speed, cost-efficiency, and quality. Industry consensus has long suggested that prioritizing two of these factors inevitably means compromising on the third. Advanced Medicine Partners challenges this view, arguing that compromising any of these key elements ultimately harms patients, regulators, and the biopharma industry. For instance, cutting corners on quality can lead to adverse patient outcomes, regulatory setbacks, and reduced company value, while sacrificing speed means longer waits for life-saving treatments, prolonging the suffering of patients and their families.

Rather than accept these tradeoffs, Advanced Medicine Partners advocates for a new paradigm where quality, speed, and cost-effectiveness are all achievable without compromise. By leveraging efficient processes, proven manufacturing platforms, and expert teams, they aim to bring advanced therapies to market swiftly, while ensuring high-quality treatments remain accessible to patients. Learn more about how they are redefining the development of advanced therapies and setting new industry standards.